Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Reusable Bioreactors Market: Large-Volume Commercial Biologics Production and CDMO Capacity Expansion to Drive Market Growth

The global reusable bioreactors market was valued at USD 9.7 billion in 2025 and is projected to reach USD 24.02 billion by 2035, expanding at a CAGR of 10.6%. Reusable bioreactors — traditionally stainless steel stirred-tank reactors and glass vessels that can be cleaned, sterilised, and reused across multiple production batches — represent the established large-scale commercial manufacturing platform for the majority of approved biologic drugs including monoclonal antibodies, recombinant proteins, vaccines, and biosimilars produced at volumes above 2,000 litres. Despite the industry shift toward single-use bioreactor adoption at small and pilot scale, reusable stainless steel systems retain dominant market share at commercial scale due to their superior durability for long-running continuous production campaigns, lower per-batch material cost at high volume, and established regulatory acceptance in cGMP manufacturing environments.

Stirred-tank bioreactors are the dominant product type, reflecting their versatility across mammalian cell culture and microbial fermentation applications at the full range of production scales from laboratory through large-scale commercial. Mammalian cell culture is the dominant application, anchored by the CHO and HEK293 cell platforms that produce the majority of approved biologic drugs. Pharmaceutical and biopharmaceutical manufacturers are the largest end-user, but CDMOs are growing fastest as contract manufacturing capacity expansion creates the largest single category of new reusable bioreactor procurement — particularly at very large scale (10,000L to 25,000L) where single-use bioreactor technology does not currently offer commercially viable equivalent systems.

Executive Snapshot

What is the confirmed market size and growth trajectory for the global reusable bioreactors market?
The market was valued at USD 9.7 billion in 2025 and is projected to grow at a CAGR of 10.6% to USD 24.02 billion by 2035. Stirred-tank bioreactors are the dominant product type. Mammalian cell culture is the dominant application. Pharmaceutical manufacturers are the largest end-user; CDMOs are fastest-growing. North America leads; Asia-Pacific is fastest-growing. Large scale above 1,000L is dominant by revenue; very large scale above 10,000L is growing fastest.

Why do reusable stainless steel bioreactors retain commercial-scale dominance despite single-use growth?
At commercial production scale above 2,000 litres, stainless steel bioreactors retain economic dominance because the per-batch cost of single-use bioreactor bags at large volumes — which can reach USD 50,000 to USD 300,000 per bag — becomes commercially prohibitive compared to the amortised cost of validated stainless steel vessels running dozens to hundreds of batches. For blockbuster biologic drugs producing tens to hundreds of kilograms of protein annually, stainless steel cost-per-gram is materially lower than single-use — sustaining reusable bioreactor capital procurement at very large scale even as single-use penetration grows at smaller scales.

How does biosimilar manufacturing drive reusable bioreactor demand at large commercial scale?
Biosimilar manufacturing — producing copies of reference biologic drugs at lower cost for established high-volume markets, including adalimumab, trastuzumab, and bevacizumab biosimilars — requires large-volume reusable stainless steel bioreactor capacity because biosimilar economics depend on cost per gram of protein below the reference biologic’s branded cost structure. Biosimilar producers in Korea, China, and India invest in very large-scale (10,000 L to 25,000 L) stainless steel bioreactor trains that produce the bulk volume required to compete on price in regulated biosimilar markets — creating consistent large-scale reusable bioreactor procurement from the biosimilar manufacturing sector.

What role does Sartorius play in the reusable bioreactors market and what does its USD 3.5 billion revenue confirm?
Sartorius — the German bioprocess technology company in which Bio-Rad Laboratories holds a USD 5.67 billion fair-value investment representing approximately 38% of ordinary shares – reported approximately EUR 3.5 billion in 2025 revenue across its Bioprocess Solutions Division and Lab Products and Services Division. Sartorius’s BIOSTAT STR and BIOSTAT C reusable bioreactor platforms are among the market’s most widely deployed stirred-tank bioreactor systems in pharmaceutical production, sustaining Sartorius as a primary commercial-scale reusable bioreactor supplier alongside Cytiva.

How does continuous biomanufacturing using reusable perfusion bioreactors create a structural competitive advantage?
Continuous biomanufacturing — where reusable perfusion bioreactors operate with continuous media exchange and product harvest rather than batch cycling — achieves product concentration 10x to 30x above conventional fed-batch in equivalent bioreactor volume, reducing manufacturing facility footprint and capital investment for equivalent production output. The FDA and EMA have issued guidance supporting continuous manufacturing adoption, creating regulatory tailwind for reusable perfusion bioreactor investment in new biopharma manufacturing facilities designed from the outset for intensified continuous production.

How does the Danaher Cytiva Biotechnology segment position reusable bioreactors within its integrated bioprocessing platform?
Danaher’s Cytiva Biotechnology segment – established through the 2015 Pall acquisition and transformationally expanded through the 2020 Cytiva (GE Healthcare Life Sciences) USD 21 billion acquisition – offers integrated reusable bioreactor systems, including the BIOSTAT and Xcellerex bioreactor platforms, alongside downstream chromatography, filtration, and analytics that together serve the complete biomanufacturing workflow. This integrated platform positioning differentiates Cytiva’s reusable bioreactor offering from equipment-only competitors by providing process development to commercial scale continuity within a single equipment ecosystem.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Reusable Bioreactors Market

  • Very large scale reusable bioreactors above 10,000L are growing fastest as biosimilar and vaccine manufacturers invest in economy-of-scale commercial production capacity. Biosimilar and vaccine manufacturers building 10,000L to 25,000L stainless steel bioreactor capacity for cost-competitive high-volume commercial production growing fastest within reusable bioreactor scale segments.
  • Hybrid facilities combining reusable large-scale and single-use small-scale bioreactors are the fastest-growing facility design as biopharma flexibility requirements increase. Hybrid biomanufacturing facilities pairing reusable commercial-scale bioreactors with single-use development and clinical bioreactors growing fastest as biopharma operators seek commercial scale economics with development flexibility within unified manufacturing environments.
  • Intensified bioprocessing using reusable perfusion bioreactors is growing as continuous manufacturing regulatory guidance clarifies pathway to approval. Reusable perfusion bioreactor continuous manufacturing growing as FDA and EMA guidance reduces regulatory uncertainty and demonstrates pathway to approval for continuous biomanufacturing processes.
  • Vaccine production reusable bioreactor demand is growing as global pandemic preparedness investment creates new large-scale vaccine manufacturing capacity. Post-COVID pandemic preparedness investment creating new government-funded large-scale vaccine manufacturing bioreactor capacity from BARDA, CEPI, and national health security programmes.
  • Microbial fermentation reusable bioreactor demand is growing from precision fermentation — producing dairy proteins, food ingredients, and speciality chemicals via engineered microorganism fermentation. Precision fermentation applications using reusable stirred-tank fermenters for dairy-identical proteins, heme ingredients, and speciality chemical production growing as food biotech scales commercial fermentation capacity.
  • Digital twin and process control software integration within reusable bioreactor systems is growing as manufacturing digital transformation creates demand for data-rich process management. Digital twin modelling and advanced process control software integration within reusable bioreactor automation systems growing as biopharma manufacturing digital transformation creates demand for real-time process optimisation above conventional PID control.

Market Segmentation: Reusable Bioreactors Market

By Usage
  • Developmental, Preclinical & Clinical
  • Commercial Production
By Material
  • Stainless Steel
  • Glass
  • Others
By Process Type
  • Batch
  • Fed-Batch
  • Continuous (Perfusion)
By Control Type
  • Manual Bioreactors
  • Semi-Automated Bioreactors
  • Fully Automated Bioreactors
By Capacity
  • Up to 50 L
  • 51–250 L
  • 251–500 L
  • 501–1,000 L
  • 1,001–2,000 L
  • 2,001–5,000 L
  • 5,001–10,000 L
  • Above 10,000 L
By Application
  • Biopharmaceutical Production
  • Vaccine Production
  • Cell & Gene Therapy Manufacturing
  • Tissue Engineering & Regenerative Medicine
  • Stem Cell Research
  • Microbial Fermentation
  • Biosimilar Production
  • Other Applications
By End User
  • Research & Development (R&D) Organizations
  • Biopharmaceutical Manufacturers
  • Contract Manufacturing Organizations (CMOs/CDMOs)
  • Academic & Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Reusable Bioreactors Market

  1. Commercial-scale economics of stainless steel per-gram cost below single-use bag cost sustaining reusable bioreactor dominance at large scale. Stainless steel per-batch cost economics sustaining reusable dominance at large commercial scale where single-use bag replacement cost becomes commercially prohibitive per batch.
  2. Biosimilar manufacturer large-scale reusable bioreactor investment for cost-competitive high-volume production. Biosimilar manufacturers investing in very large scale stainless steel bioreactors for cost-per-gram economics enabling price competition in regulated biosimilar markets.
  3. Sartorius EUR 3.5B revenue confirming commercial scale of reusable bioprocess platform demand. Sartorius EUR 3.5B 2025 revenue across Bioprocess Solutions and Lab Products divisions confirming commercial scale of global reusable bioreactor and bioprocessing equipment market.
  4. Continuous manufacturing perfusion reusable bioreactor regulatory guidance creating pathway for intensified production. FDA and EMA continuous manufacturing guidance reducing regulatory uncertainty and creating approved pathway for reusable perfusion bioreactor intensified production adoption.
  5. Government pandemic preparedness investment creating new large-scale vaccine manufacturing reusable bioreactor capacity. BARDA, CEPI, and national pandemic preparedness programmes funding new large-scale vaccine manufacturing bioreactor investment creating non-discretionary public sector procurement.
  6. Precision fermentation commercial scale investment creating new industrial fermentation reusable bioreactor demand from food biotech. Precision fermentation commercial scale investment from alternative protein and food ingredient companies creating new industrial fermentation reusable stirred-tank bioreactor procurement.

Regional Outlook: Reusable Bioreactors Market

  • North America: Dominant reusable bioreactor market anchored by major biopharma manufacturers’ commercial production facilities and the world’s highest CDMO capacity concentration. Cytiva’s BIOSTAT and Xcellerex platforms and Thermo Fisher’s HyPerforma Pro controlled process vessels serve North America’s pharmaceutical manufacturing leadership.
  • Europe: Significant established market where Sartorius’ German-headquartered BIOSTAT bioreactor platform and Eppendorf’s bioprocess systems serve European pharmaceutical manufacturing hubs. EU pharmaceutical manufacturing in Germany, Switzerland, Ireland, and Denmark creates the world’s highest density of reusable bioreactor installed base relative to GDP.
  • Asia-Pacific: Fastest-growing reusable bioreactor market driven by South Korea’s Samsung Biologics and Celltrion CDMO mega-facility investments, China’s domestic biosimilar manufacturing scale-up, and India’s Serum Institute and Biocon vaccine and biosimilar production capacity expansion.

Competitive Landscape: Reusable Bioreactors Market

Key Players: Cytiva (Danaher Corp.), Sartorius AG, Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Eppendorf SE, Getinge AB, Pall Corporation (Danaher), Applikon Biotechnology, INFORS HT, Bioengineering AG, and Biostat AG

Recent Developments

  • Bio-Rad Laboratories’ FY2025 Annual Report filed with the SEC confirmed that as of December 31, 2025, Bio-Rad’s fair value investment in Sartorius AG was USD 5,669.2 million — representing approximately 38% of Sartorius ordinary shares — with Sartorius described as an international laboratory and process technology provider for the biotech, pharmaceutical, and food industries operating through its Bioprocess Solutions Division and Lab Products and Services Division.
  • Danaher’s FY2024 Annual Report filed with the SEC confirmed that Danaher’s Biotechnology segment was established through the Pall acquisition in 2015 and transformationally expanded through the Cytiva acquisition in 2020 — providing a broad range of bioprocessing equipment, consumables, and services including bioreactor systems that support development and manufacture of biotherapeutics including mAbs, recombinant proteins, vaccines, and cell and gene therapies.
  • Repligen Corporation’s FY2024 Annual Report filed with the SEC estimated the global addressable market for bioprocessing products at approximately USD 20 billion at year-end 2024, with Repligen’s addressable market estimated at approximately USD 12 billion — confirming the commercial scale of the reusable and single-use bioreactor and bioprocessing equipment market that encompasses reusable bioreactor systems as the largest installed-base segment.

Consultant POV

The reusable bioreactors market’s 10.6% CAGR through 2035 from a USD 9.7 billion 2025 base is structurally anchored by the commercial-scale economics that no single-use technology can displace in the near term — the per-gram cost advantage of stainless steel at very large production volumes is a function of physics and material economics that persists regardless of single-use platform innovation. Sartorius’ EUR 3.5 billion 2025 revenue and Cytiva’s position within Danaher’s bioprocessing platform confirm that the two largest reusable bioreactor equipment suppliers are sustaining investment in commercial-scale systems. The biosimilar manufacturing expansion — particularly in South Korea, China, and India — is the market’s most commercially consequential demand driver through 2035, as each new biosimilar approval creates large-scale reusable bioreactor procurement that operates for the full commercial lifecycle of the biosimilar product.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report